Business

CareDx Announces Dismissal of 2021 Qui Tam Suit

BRISBANE, Calif., May 11, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company.

articleCaredx, Inc.May 11, 20261/company/caredx-inc/news/caredx-announces-dismissal-of-2021-qui-tam-suit
CareDx Announces Dismissal of 2021 Qui Tam Suit

About this update from Caredx, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/bd8f2e81a46dbc2a45cb96705b3beb27"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8oFiNsBpnW0nlQf3QMAQRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/bd8f2e81a46dbc2a45cb96705b3beb27","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0nfEguumTpr5Yj0Y3Gbgyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/bd8f2e81a46dbc2a45cb96705b3beb27","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QTJ263wV4i5qJRPplEzdyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/bd8f2e81a46dbc2a45cb96705b3beb27","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BRISBANE, Calif., May 11, 2026--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company.","length":380,"tagName":"p"},{"type":"text","content":"On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter.","length":127,"tagName":"p"},{"type":"text","content":"There is no monetary payment associated with the dismissal.","length":59,"tagName":"p"},{"type":"text","content":"The dismissal order follows the request, by the qui tam plaintiff, for dismissal of the case and the Department of Justice's (DOJ) concurrence in that request.","length":163,"tagName":"p"},{"type":"text","content":"The matter was initially filed on February 12, 2021 and led to a DOJ investigation. On October 8, 2024, CareDx announced that the DOJ had concluded its investigation into CareDx without any finding of wrongdoing and declined to take further action. CareDx has denied allegations of wrongdoing throughout.","length":304,"tagName":"p"},{"type":"text","content":"About CareDx","length":12,"tagName":"p"},{"type":"text","content":"CareDx is a precision medicine company ded...

More updates from Caredx, Inc.

CareDx, Inc.transplant patientshealthcare solutionsUnited States District Court for the Eastern District of New YorkDOJ investigation